Clinical Trial Update: High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating high-dose furmonertinib for advanced, metastatic non-small cell lung cancer in patients who progressed after first- or secon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Changhai Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING